ANVRX
Price
$10.95
Change
-$0.00 (-0.00%)
Updated
Jun 2 closing price
Net Assets
551.01M
TROZX
Price
$26.46
Change
+$0.16 (+0.61%)
Updated
Jun 2 closing price
Net Assets
17.12B
Interact to see
Advertisement

ANVRX vs TROZX

Header iconANVRX vs TROZX Comparison
Open Charts ANVRX vs TROZXBanner chart's image
ANVRX vs TROZX Comparison Chart in %
View a ticker or compare two or three
VS
ANVRX vs. TROZX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANVRX is a Hold and TROZX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
TROZX has more cash in the bank: 17.1B vs. ANVRX (551M). ANVRX (3.06) and TROZX (2.95) have matching dividends . ANVRX was incepted earlier than TROZX: ANVRX (7 years) vs TROZX (6 years). ANVRX (1.68) is less costly to investors than TROZX (0.65). ANVRX is a more actively managed with annual turnover of: 71.00 vs. TROZX (15.00). TROZX has a lower initial minimum investment than ANVRX: TROZX (0) vs ANVRX (2500). TROZX annual gain was more profitable for investors over the last year : 30.42 vs. ANVRX (16.33). TROZX return over 5 years is better than : 91.32 vs. ANVRX (14.75).
ANVRXTROZXANVRX / TROZX
Total Expense Ratio1.680.00-
Annual Report Gross Expense Ratio1.680.65258%
Fund Existence7 years6 years-
Gain YTD7.14311.34663%
Front LoadN/AN/A-
Min. Initial Investment25000-
Min. Initial Investment IRAN/AN/A-
Net Assets551M17.1B3%
Annual Yield % from dividends3.062.95104%
Returns for 1 year16.3330.4254%
Returns for 3 years22.0992.9324%
Returns for 5 years14.7591.3216%
Returns for 10 yearsN/AN/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TMP86.090.94
+1.10%
Tompkins Financial Corp
ITUB7.860.07
+0.94%
Itau Unibanco Banco Holding SA
QS9.200.06
+0.66%
QuantumScape Corp
ASPC11.05-0.01
-0.05%
A Spac III Acquisition Corp
CNTX2.42-0.37
-13.26%
Context Therapeutics